 |
|
|
| |
Long-term efficacy of bictegravir/emtricitabine/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with preexisting resistance and viral blips
|
| |
| |
EACS 2021 Oct 27-30
K. Andreatta1, S. Chang1, M. Delaney1, M. Willkom1, R. Martin1, H. Graham1, H. Martin1, K.L. White1
1Gilead Sciences, Inc., Foster City, United States
|
| |
|
|
|
|
|
